Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Gene therapy, gene editing and perspectives on future use in Parkinson’s disease

By Alice Waterhouse

Patient Clinical Trial & Communications Plan Review: A Customer Story

Our client reached out to Impetus to help establish a virtual patient panel with the aim to gather insights on their unmet needs, the most important attributes of treatment, and the impact of...

Impetus Digital

- PMLiVE

Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023

During the 2023 annual meeting of ACOG, Medscape highlighted the outcomes of CME/CE programs focused on improving clinicians knowledge and achieving better outcomes for patients. The outcomes were shared through...

Medscape Education

- PMLiVE

FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis

Ayvakit is now the first and only approved medicine designed to treat the underlying cause of the disease

- PMLiVE

Decision date for Sarepta’s Duchenne muscular dystrophy gene therapy delayed by FDA

The disease occurs in up to one in every 5,000 newborn males worldwide

- PMLiVE

The need for a refreshingly different approach to achieving behaviour change

By Laura Glover

- PMLiVE

Almirall and CRG announce non-melanoma skin cancer research collaboration

The partners will jointly develop novel preclinical models to identify new treatments for NMSC

- PMLiVE

Seqera Labs and Genomics England partner to progress genomic research

The collaboration is aimed at helping more patients benefit from genomic healthcare

- PMLiVE

Medscape Collaborates for Health Equity at DDW 2023

Recently, DDW 2023 took place in Chicago, IL, and Medscape was on-site with patient advocacy organizations to help educate clinicians on health equity in gastroenterology.Medscape was joined during the conference...

Medscape Education

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

- PMLiVE

Novo Nordisk announces positive phase 3 results for oral weight-loss drug

Semaglutide is already available in major markets as a once-weekly injection

- PMLiVE

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

About 100,000 people are living with the progressive condition in the US alone

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links